The class action, filed in the U.S. District Court for the District of Massachusetts under the caption Hu v. Insulet Corporation et al., targets the company and select senior executives for alleged violations of the Securities Exchange Act of 1934. The complaint centers on claims that Insulet prioritized a narrative of medical-grade quality while concealing manufacturing defects that compromised patient safety.

Investors suffered losses after the company disclosed internal tubing tears in its Omnipod 5 Pods. A March 12, 2026, announcement regarding a voluntary medical device correction caused shares to slide 6.88%. A second correction in May 2026, affecting the Omnipod 5, DASH, and Eros systems due to similar under-delivery risks, triggered a further 5.07% drop. The law firm Bleichmar Fonti & Auld LLP, which is spearheading the litigation, has set an August 31, 2026, deadline for shareholders seeking to serve as lead plaintiffs.